USC Stevens Center for Innovation: Leading Corporate Partnerships at USC
At USC, we believe in a culture of partnership and collaboration. Together with our partners, we strive to bring together the right people and resources to accelerate the translation of basic research into tangible products and services. We have learned that the right people, transparent processes, and flexible collaboration models are the key to success.
For more information, contact Lawrence Lau, Associate Director of Corporate Collaborations, at firstname.lastname@example.org or 213-821-0947.
Pfizer Centers for Therapeutic Innovation
Accelerating translation of novel targets to the clinic
USC is part of this innovative Pharma program with leading university and academic research centers nationwide. USC has a master research collaboration agreement with Pfizer CTI that focuses on large molecule targets. USC faculty awardees to date are Dr. Parkash Gill and Dr. Alan Epstein, who have been awarded significant funding from Pfizer CTI to accelerate their research in cancer and immune-oncology respectively.
New international open source research coalition
The GPCR Consortium is a public-private open source partnership to advance GPCR (G-protein-coupled receptors) research for drug development and bolsters USC’s efforts to promote biomedical research in Los Angeles. There are 9 multinational pharmaceutical companies (Amgen, Sanofi, Ono, Pfizer, Merck, Lundbeck, Novo Nordisk, Taisho, Boehringer Ingelheim) that are part of this consortium which has exceeded expectations and USC has received significant funding to date in sponsored research. Projects are led by Dr. Ray Stevens and include interdisciplinary collaborators at USC such as Drs. Carl Kesselman, Vadim Cherezov, and Seva Katrich.
Single cell early access partnership
As an Early Access partner with Fluidigm Corp., USC is the first academic center to apply a novel imaging mass cytometer (IMC) platform, expected to revolutionize the understanding of spatial arrangement, function and communication of single cells in solid tissue. The partnership with Fluidigm will accelerate the application of high-resolution, single cell biology research through the interaction of critical shared resources at USC with public and private partners in pioneering fields such as cancer biology, stem cells, engineering and informatics. Projects are being led by Drs. Peter Kuhn, Jim Hicks and Scott Fraser.
Collaborative R&D focusing on innovation for patient-driven advances in cancer treatment
Emulate, Inc.’s strategic collaboration with the Lawrence J. Ellison Institute for Transformative Medicine of USC will use Emulate’s Organs-on-Chips technology to conduct leading-edge translational R&D that can advance cancer treatment and patient well-being. Emulate and the Ellison Institute will collaborate on innovative approaches for modeling the human physiology of cancer and predicting human response to treatments, expanding the functionality and applications of using the Organs-on-Chips technology in cancer research. This R&D initiative is part of Emulate’s growing network of collaborators and is designed to foster translational research to expand the range of academic, commercial and clinical applications for Emulate’s Human Emulation System™.